Zobrazeno 1 - 10
of 197
pro vyhledávání: ''
Publikováno v:
Thrombosis Research. 196:510-515
Introduction On-treatment platelet aggregability represents the major form of functional assessment for patients treated with P2Y12 receptor antagonists, with “high” on-treatment platelet aggregability (HTPA) predicting thrombotic risk. However H
Autor:
Maria Fernström, Anita Hurtig-Wennlöf, Ulrika Fernberg, Liza U. Ljungberg, Knut Fälker, Madelene Lindkvist, Magnus Grenegård
Publikováno v:
Thrombosis Research. 174:5-12
Introduction Platelet aggregation and secretion can be induced by a large number of endogenous activators, such as collagen, adenosine diphosphate (ADP) and epinephrine. Conversely, the blood vessel endothelium constitutively release platelet inhibit
Autor:
Claire Roome, Scott Harris, Rod Stables, Nick Curzen, Ian Kemp, Vikram Khanna, Adeel Shahzad, Christine Mars, Keith Wilson, Kala Thayalasamy, Rob Cooper
Publikováno v:
THROMBOSIS RESEARCH
In randomised trials, bivalirudin has been associated with higher rates of acute stent thrombosis (AST) compared to unfractionated heparin (UFH), without mechanistic explanation. Furthermore, data are discrepant regards the antiplatelet effects of bi
Autor:
Andrew L. Frelinger, Joseph A. Jakubowski, Stipo Jurcevic, Neehar Gupta, Chunmei Zhou, Jo Howard, Timothy Mant, Christopher D. Payne, D. Richard Lachno, Kenneth J. Winters
Publikováno v:
Thrombosis Research. 133:190-195
Introduction Prasugrel, a P2Y12 adenosine diphosphate (ADP) receptor antagonist effectively inhibits ADP-mediated platelet activation and aggregation, and may be useful in reducing vaso-occlusive crises in sickle cell disease (SCD). In this study, we
Autor:
Mirta Schattner, Julia Etulain, Agostina Carestia, Soledad Negrotto, Leonardo Rivadeneyra, Carlos Fondevila, Roberto Gabriel Pozner
Publikováno v:
Thrombosis Research. 133:235-243
INTRODUCTION: Platelets express Toll-like receptors (TLRs) that recognise molecular components of pathogens and, in nucleated cells, elicit immune responses through nuclear factor-kappaB (NF-κB) activation. We have shown that NF-κB mediates platele
Autor:
Jerrold H. Levy, Atsuhiro Sugidachi, Fania Szlam, Kenichi A. Tanaka, Michael Mazzeffi, Joseph A. Jakubowski
Publikováno v:
Thrombosis Research. 132:106-111
Introduction Prasugrel is a thienopyridyl P2Y12 antagonist with potent antiplatelet effects. At present, little is known about its effects on thrombin generation or what strategies may emergently reverse its anticoagulant effects. In the current stud
Autor:
Anna Falanga, Carmen J Tartari, Marina Marchetti, Laura Russo, Hugo ten Cate, Anna Leuzzi, Guido Finazzi, Marina Panova-Noeva, Alessandro Rambaldi
Publikováno v:
Thrombosis Research, 132(1), 88-93. Elsevier Science
Introduction Essential Thrombocythemia (ET) and Polycythemia Vera (PV) patients are characterized by an increased rate of thrombotic complications and by several abnormalities of platelets, more pronounced in JAK2V617F positive patients. The aim of t
Publikováno v:
Thrombosis Research. 130:409-414
Introduction Curdione, one of the major sesquiterpene compounds from Rhizoma Curcumae, has been shown to exhibit multiple bioactive properties. In this study, we investigated the anti-platelet aggregation and antithrombotic activities of curdione wit
Autor:
Shu-Ting Ren, Yi-Ran Liao, Ying-Xue Li, Qiang Sun, Ya Wang, Xin-Liang Shen, Bing Wang, Hui Zhang
Publikováno v:
Thrombosis Research. 129:e217-e222
Introduction Z4A5 is a novel peptide that inhibits platelet aggregation and formation of platelet thrombi, but the mechanism of its anti-platelet effects remains unknown. This study explores the anti-platelet effect and mechanism of Z4A5. Methods We
Autor:
Daniela Seidinger, Simon Panzer, Christine Mannhalter, Thomas Gremmel, Deddo Moertl, Renate Koppensteiner, Christoph W. Kopp, Sabine Steiner
Publikováno v:
Thrombosis Research. 129:616-622
Background The antiplatelet effect of clopidogrel has been linked to cytochrome P450 2C19 (CYP2C19) carrier status. The presence of loss of function and gain of function variants were found to have a gene-dose effect on clopidogrel metabolism. Howeve